News
GCAN
0.145
NaN%
--
Weekly Report: what happened at GCAN last week (0525-0529)?
Weekly Report · 3d ago
Weekly Report: what happened at GCAN last week (0518-0522)?
Weekly Report · 05/25 09:22
Weekly Report: what happened at GCAN last week (0511-0515)?
Weekly Report · 05/18 09:22
Greater Cannabis net loss narrows to $33,376 in Q1 FY26; reports no revenue
PUBT · 05/13 13:04
Weekly Report: what happened at GCAN last week (0504-0508)?
Weekly Report · 05/11 09:21
Weekly Report: what happened at GCAN last week (0427-0501)?
Weekly Report · 05/04 09:21
Weekly Report: what happened at GCAN last week (0420-0424)?
Weekly Report · 04/27 09:21
Weekly Report: what happened at GCAN last week (0413-0417)?
Weekly Report · 04/20 09:20
Weekly Report: what happened at GCAN last week (0406-0410)?
Weekly Report · 04/13 09:21
Weekly Report: what happened at GCAN last week (0330-0403)?
Weekly Report · 04/06 09:22
Greater Cannabis FY25 net loss widens to $331,612
Reuters · 03/31 20:23
Weekly Report: what happened at GCAN last week (0323-0327)?
Weekly Report · 03/30 09:21
Weekly Report: what happened at GCAN last week (0316-0320)?
Weekly Report · 03/23 09:21
Weekly Report: what happened at GCAN last week (0309-0313)?
Weekly Report · 03/16 09:20
Weekly Report: what happened at GCAN last week (0302-0306)?
Weekly Report · 03/09 09:21
Weekly Report: what happened at GCAN last week (0223-0227)?
Weekly Report · 03/02 09:20
Weekly Report: what happened at GCAN last week (0216-0220)?
Weekly Report · 02/23 09:20
Weekly Report: what happened at GCAN last week (0209-0213)?
Weekly Report · 02/16 09:20
Weekly Report: what happened at GCAN last week (0202-0206)?
Weekly Report · 02/09 09:21
Weekly Report: what happened at GCAN last week (0126-0130)?
Weekly Report · 02/02 09:21
More
Webull provides a variety of real-time GCAN stock news. You can receive the latest news about Greater Cannabis through multiple platforms. This information may help you make smarter investment decisions.
About GCAN
The Greater Cannabis Company, Inc. is a biotechnology company. The Company is involved in additional research and development of cannabinoid-based therapeutics that reduce disruptive symptoms in patients suffering from neuropsychiatric disorders. The Company also focuses on developing new formulations around cannabinoid therapeutics. Its wholly owned subsidiary is Biocanrx, Inc.